Supplementary Table 1 | Sensitivity and specificity metrics of common molecular
diagnostic tests for bladder cancer.
Number
of studies
analyzed
Median
sensitivity [%]
(range)
Median
specificity [%]
(range)
Supplementary
references
BTA stat®
36
67 (34–91)
76 (38–96)
1–36
BTA TRAK®
12
63 (17–100)
76 (50–98)
15, 28, 37–46
Test
NMP22®
Bladder Cancer
Test
41
72 (31–100)
80 (43–100)
6–8, 11–13, 15, 19,
20, 24–26, 30–33,
35, 40, 43–45, 47–
66
NMP22®
BladderChek®
6
57 (47–85)
86 (40–90)
67–72
UBC™-Rapid
13
67 (21–84)
80 (49–98)
14, 20, 24, 28, 30,
34, 52, 55, 58, 59,
73–75
HA–HAase
6
88 (83–91)
81 (61–93)
29, 34, 35, 76–78
UroVysion®
19
73 (13–87)
90 (40–100)
27, 32, 33, 79–94
ImmunoCyt®
16
81 (39–100)
75 (62–95)
33, 77, 94–107
Supplementary references
1.
2.
3.
4.
5.
6.
7.
Sarosdy, M.F. et al. Results of a multicenter trial using the BTA test to monitor
for and diagnose recurrent bladder cancer. J Urol 154, 379-83; discussion 383-4
(1995).
Ianari, A. et al. Results of Bard BTA test in monitoring patients with a history of
transitional cell cancer of the bladder. Urology 49, 786-9 (1997).
Sarosdy, M.F. et al. Improved detection of recurrent bladder cancer using the
Bard BTA stat test. Urology 50, 349-53 (1997).
Leyh, H. & Mazeman, E. Bard BTA test compared with voided urine cytology in
the diagnosis of recurrent bladder cancer. Eur Urol 32, 425-8 (1997).
van der Poel, H.G. et al. Bladder wash cytology, quantitative cytology, and the
qualitative BTA test in patients with superficial bladder cancer. Urology 51, 4450 (1998).
Wiener, H.G. et al. Can urine bound diagnostic tests replace cystoscopy in the
management of bladder cancer? J Urol 159, 1876-80 (1998).
Landman, J., Chang, Y., Kavaler, E., Droller, M.J. & Liu, B.C. Sensitivity and
specificity of NMP-22, telomerase, and BTA in the detection of human bladder
cancer. Urology 52, 398-402 (1998).
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Ramakumar, S. et al. Comparison of screening methods in the detection of
bladder cancer. J Urol 161, 388-94 (1999).
Pode, D. et al. Noninvasive detection of bladder cancer with the BTA stat test. J
Urol 161, 443-6 (1999).
Leyh, H. et al. Comparison of the BTA statTM test with voided urine cytology and
bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur
Urol 35, 52-6 (1999).
Sharma, S., Zippe, C.D., Pandrangi, L., Nelson, D. & Agarwal, A. Exclusion
criteria enhance the specificity and positive predictive value of NMP22 and BTA
stat. J Urol 162, 53-7 (1999).
Sozen, S. et al. Comparison of the nuclear matrix protein 22 with voided urine
cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the
bladder. Eur Urol 36, 225-9 (1999).
Giannopoulos, A. et al. Comparative evaluation of the BTAstat test, NMP22, and
voided urine cytology in the detection of primary and recurrent bladder tumors.
Urology 55, 871-5 (2000).
Mian, C. et al. Comparison of two qualitative assays, the UBC rapid test and the
BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology
56, 228-31 (2000).
Serretta, V., Pomara, G., Rizzo, I. & Esposito, E. Urinary BTA-stat, BTA-Trak
and NMP22 in surveillance after TUR of recurrent superficial transitional cell
carcinoma of the bladder. Eur Urol 38, 419-25 (2000).
Heicappell, R., Muller, M., Fimmers, R. & Miller, K. Qualitative determination of
urinary human complement factor H-related protein (hcfHrp) in patients with
bladder cancer, healthy controls, and patients with benign urologic disease. Urol
Int 65, 181-4 (2000).
Raitanen, M.P. et al. Human complement factor H related protein test for
monitoring bladder cancer. J Urol 165, 374-7 (2001).
Raitanen, M.P. et al. Analysis of false-positive BTA STAT test results in patients
followed up for bladder cancer. Urology 57, 680-4 (2001).
Gutierrez Banos, J.L., Rebollo Rodrigo, M.H., Antolin Juarez, F.M. & Martin
Garcia, B. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer:
A comparative study. Urol Int 66, 185-90 (2001).
Giannopoulos, A. et al. Comparative evaluation of the diagnostic performance of
the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and
recurrent bladder tumors. J Urol 166, 470-5 (2001).
van Rhijn, B.W., Lurkin, I., Kirkels, W.J., van der Kwast, T.H. & Zwarthoff, E.C.
Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up
of superficial bladder carcinoma: a phase II trial. Cancer 92, 768-75 (2001).
Walsh, I.K., Keane, P.F., Ishak, L.M. & Flessland, K.A. The BTA stat test: a
tumor marker for the detection of upper tract transitional cell carcinoma. Urology
58, 532-5 (2001).
Raitanen, M.P. et al. Effect of intravesical instillations on the human complement
factor H related protein (BTA stat) test. Eur Urol 40, 422-6 (2001).
Boman, H., Hedelin, H. & Holmang, S. Four bladder tumor markers have a
disappointingly low sensitivity for small size and low grade recurrence. J Urol
167, 80-3 (2002).
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
Saad, A. et al. A study comparing various noninvasive methods of detecting
bladder cancer in urine. BJU Int 89, 369-73 (2002).
Poulakis, V. et al. A comparison of urinary nuclear matrix protein-22 and bladder
tumour antigen tests with voided urinary cytology in detecting and following
bladder cancer: the prognostic value of false-positive results. BJU Int 88, 692-701
(2001).
Halling, K.C. et al. A comparison of BTA stat, hemoglobin dipstick, telomerase
and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J
Urol 167, 2001-6 (2002).
Babjuk, M. et al. Qualitative and quantitative detection of urinary human
complement factor H-related protein (BTA stat and BTA TRAK) and fragments
of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell
carcinoma of the bladder. Eur Urol 41, 34-9 (2002).
Lokeshwar, V.B. et al. Bladder tumor markers for monitoring recurrence and
screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests.
Cancer 95, 61-72 (2002).
Boman, H., Hedelin, H., Jacobsson, S. & Holmang, S. Newly diagnosed bladder
cancer: The relationship of initial symptoms, degree of microhematuria and tumor
marker status. J Urol 168, 1955-9 (2002).
Bhuiyan, J., Akhter, J. & O'Kane, D.J. Performance characteristics of multiple
urinary tumor markers and sample collection techniques in the detection of
transitional cell carcinoma of the bladder. Clin Chim Acta 331, 69-77 (2003).
Friedrich, M.G. et al. Comparison of multitarget fluorescence in situ hybridization
in urine with other noninvasive tests for detecting bladder cancer. BJU Int 92,
911-4 (2003).
Toma, M.I. et al. Comparison of the ImmunoCyt test and urinary cytology with
other urine tests in the detection and surveillance of bladder cancer. World J Urol
22, 145-9 (2004).
Schroeder, G.L. et al. A side by side comparison of cytology and biomarkers for
bladder cancer detection. J Urol 172, 1123-6 (2004).
Sun, Y. et al. Comparison of seven screening methods in the diagnosis of bladder
cancer. Chin Med J (Engl) 119, 1763-71 (2006).
Raitanen, M.P. The role of BTA stat Test in follow-up of patients with bladder
cancer: results from FinnBladder studies. World J Urol (2008).
Abbate, I. et al. Comparison of nuclear matrix protein 22 and bladder tumor
antigen in urine of patients with bladder cancer. Anticancer Res 18, 3803-5
(1998).
Thomas, L. et al. Multicenter trial of the quantitative BTA TRAK assay in the
detection of bladder cancer. Clin Chem 45, 472-7 (1999).
Malkowicz, S.B. The application of human complement factor H-related protein
(BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 27,
63-73, ix (2000).
Casetta, G. et al. BTA quantitative assay and NMP22 testing compared with urine
cytology in the detection of transitional cell carcinoma of the bladder. Urol Int 65,
100-5 (2000).
Priolo, G. et al. Bladder tumor antigen assay as compared to voided urine
cytology in the diagnosis of bladder cancer. Clin Chim Acta 305, 47-53 (2001).
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
Gibanel, R. et al. BTA TRAK urine test increases the efficacy of cytology in the
diagnosis of low-grade transitional cell carcinoma of the bladder. Anticancer Res
22, 1157-60 (2002).
Mahnert, B. et al. Measurements of complement factor H-related protein (BTATRAK assay) and nuclear matrix protein (NMP22 assay) – Useful diagnostic
tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med 41, 104-10
(2003).
Abd El Gawad, I.A. et al. Comparative study of NMP-22, telomerase, and BTA in
the detection of bladder cancer. J Egypt Natl Canc Inst 17, 193-202 (2005).
Tsui, K.H. et al. Comparisons of voided urine cytology, nuclear matrix protein-22
and bladder tumor associated antigen tests for bladder cancer of geriatric male
patients in Taiwan, China. Asian J Androl 9, 711-5 (2007).
Babjuk, M. et al. Urinary cytology and quantitative BTA and UBC tests in
surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 71,
718-22 (2008).
Witjes, J.A., van der Poel, H.G., van Balken, M.R., Debruyne, F.M. & Schalken,
J.A. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients
with superficial bladder cancer. Eur Urol 33, 387-91 (1998).
Serretta, V. et al. Urinary NMP22 for the detection of recurrence after
transurethral resection of transitional cell carcinoma of the bladder: experience on
137 patients. Urology 52, 793-6 (1998).
Zippe, C., Pandrangi, L. & Agarwal, A. NMP22 is a sensitive, cost-effective test
in patients at risk for bladder cancer. J Urol 161, 62-5 (1999).
Miyanaga, N. et al. Urinary nuclear matrix protein 22 as a new marker for the
screening of urothelial cancer in patients with microscopic hematuria. Int J Urol
6, 173-7 (1999).
Sanchez-Carbayo, M., Herrero, E., Megias, J., Mira, A. & Soria, F. Evaluation of
nuclear matrix protein 22 as a tumour marker in the detection of transitional cell
carcinoma of the bladder. BJU Int 84, 706-13 (1999).
Mian, C. et al. Comparison of the monoclonal UBC-ELISA test and the NMP22
ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology
55, 223-6 (2000).
Casella, R. et al. Urinary level of nuclear matrix protein 22 in the diagnosis of
bladder cancer: experience with 130 patients with biopsy confirmed tumor. J Urol
164, 1926-8 (2000).
Lahme, S., Bichler, K.H., Feil, G. & Krause, S. Comparison of cytology and
nuclear matrix protein 22 for the detection and follow-up of bladder cancer. Urol
Int 66, 72-7 (2001).
Sanchez-Carbayo, M. et al. Comparative predictive values of urinary cytology,
urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating
symptomatic patients at risk for bladder cancer. J Urol 165, 1462-7 (2001).
Ponsky, L.E. et al. Screening and monitoring for bladder cancer: refining the use
of NMP22. J Urol 166, 75-8 (2001).
Chahal, R., Darshane, A., Browning, A.J. & Sundaram, S.K. Evaluation of the
clinical value of urinary NMP22 as a marker in the screening and surveillance of
transitional cell carcinoma of the urinary bladder. Eur Urol 40, 415-20; discussion
421 (2001).
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
Sanchez-Carbayo, M., Urrutia, M., Gonzalez de Buitrago, J.M. & Navajo, J.A.
Utility of serial urinary tumor markers to individualize intervals between
cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 92,
2820-8 (2001).
Eissa, S. et al. Comparative evaluation of the nuclear matrix protein, fibronectin,
urinary bladder cancer antigen and voided urine cytology in the detection of
bladder tumors. J Urol 168, 465-9 (2002).
Parekattil, S.J., Fisher, H.A. & Kogan, B.A. Neural network using combined urine
nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary
intercellular adhesion molecule-1 to detect bladder cancer. J Urol 169, 917-20
(2003).
Chang, Y.H. et al. Evaluation of nuclear matrix protein-22 as a clinical diagnostic
marker for bladder cancer. Urology 64, 687-92 (2004).
Shariat, S.F. et al. Variability in the performance of nuclear matrix protein 22 for
the detection of bladder cancer. J Urol 176, 919-26; discussion 926 (2006).
Mansoor, I., Calam, R.R. & Al-Khafaji, B. Role of urinary NMP-22 combined
with urine cytology in follow-up surveillance of recurring superficial bladder
urothelial carcinoma. Anal Quant Cytol Histol 30, 25-32 (2008).
Kapila, K. et al. Could nuclear matrix protein 22 (NMP22) play a role with urine
cytology in screening for bladder cancer? – experience at Kuwait University.
Cytopathology 19, 369-74 (2008).
Jamshidian, H., Kor, K. & Djalali, M. Urine concentration of nuclear matrix
protein 22 for diagnosis of transitional cell carcinoma of bladder. Urol J 5, 243-7
(2008).
Gupta, N.P., Sharma, N. & Kumar, R. Nuclear matrix protein 22 as adjunct to
urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
Urology 73, 592-6; discussion 596-7 (2009).
Grossman, H.B. et al. Detection of bladder cancer using a point-of-care proteomic
assay. JAMA 293, 810-6 (2005).
Moonen, P.M., Kiemeney, L.A. & Witjes, J.A. Urinary NMP22 BladderChek test
in the diagnosis of superficial bladder cancer. Eur Urol 48, 951-6; discussion 956
(2005).
Grossman, H.B. et al. Surveillance for recurrent bladder cancer using a point-ofcare proteomic assay. JAMA 295, 299-305 (2006).
Kumar, A., Kumar, R. & Gupta, N.P. Comparison of NMP22 BladderChek test
and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol
36, 172-5 (2006).
Tritschler, S. et al. Validation of the diagnostic value of NMP22® BladderChek®
test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 51, 4037; discussion 407-8 (2007).
Lotan, Y. & Shariat, S.F. Impact of risk factors on the performance of the nuclear
matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 101,
1362-7 (2008).
Mungan, N.A., Vriesema, J.L., Thomas, C.M., Kiemeney, L.A. & Witjes, J.A.
Urinary bladder cancer test: a new urinary tumor marker in the follow-up of
superficial bladder cancer. Urology 56, 787-92 (2000).
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
Zargar, M., Soleimani, M. & Moslemi, M. Comparative evaluation of urinary
bladder cancer antigen and urine cytology in the diagnosis of bladder cancer. Urol
J 2, 137-40 (2005).
Gkialas, I. et al. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA
21-1, and urinary bladder cancer antigen for detection of high-grade bladder
carcinoma. Urology 72, 1159-63 (2008).
Lokeshwar, V.B. et al. Urinary hyaluronic acid and hyaluronidase: markers for
bladder cancer detection and evaluation of grade. J Urol 163, 348-56 (2000).
Hautmann, S. et al. Immunocyt and the HA-HAase urine tests for the detection of
bladder cancer: A side-by-side comparison. Eur Urol 46, 466-71 (2004).
Eissa, S. et al. Detection of bladder carcinoma by combined testing of urine for
hyaluronidase and cytokeratin 20 RNAs. Cancer 103, 1356-62 (2005).
Inoue, T. et al. Chromosomal numerical aberrations of exfoliated cells in the urine
detected by fluorescence in situ hybridization: clinical implication for the
detection of bladder cancer. Urol Res 28, 57-61 (2000).
Halling, K.C. et al. A comparison of cytology and fluorescence in situ
hybridization for the detection of urothelial carcinoma. J Urol 164, 1768-75
(2000).
Sarosdy, M.F. et al. Clinical evaluation of a multi-target fluorescent in situ
hybridization assay for detection of bladder cancer. J Urol 168, 1950-4 (2002).
Placer, J., Espinet, B., Salido, M., Sole, F. & Gelabert-Mas, A. Clinical utility of a
multiprobe FISH assay in voided urine specimens for the detection of bladder
cancer and its recurrences, compared with urinary cytology. Eur Urol 42, 547-52
(2002).
Skacel, M. et al. Multitarget fluorescence in situ hybridization assay detects
transitional cell carcinoma in the majority of patients with bladder cancer and
atypical or negative urine cytology. J Urol 169, 2101-5 (2003).
Varella-Garcia, M., Akduman, B., Sunpaweravong, P., Di Maria, M.V. &
Crawford, E.D. The UroVysion fluorescence in situ hybridization assay is an
effective tool for monitoring recurrence of bladder cancer. Urol Oncol 22, 16-9
(2004).
Laudadio, J. et al. Fluorescence in situ hybridization for detecting transitional cell
carcinoma: implications for clinical practice. BJU Int 96, 1280-5 (2005).
Krause, F.S., Rauch, A., Schrott, K.M. & Engehausen, D.G. Clinical decisions for
treatment of different staged bladder cancer based on multitarget fluorescence in
situ hybridization assays? World J Urol 24, 418-22 (2006).
Sarosdy, M.F. et al. Use of a multitarget fluorescence in situ hybridization assay
to diagnose bladder cancer in patients with hematuria. J Urol 176, 44-7 (2006).
Junker, K., Fritsch, T., Hartmann, A., Schulze, W. & Schubert, J. Multicolor
fluorescence in situ hybridization (M-FISH) on cells from urine for the detection
of bladder cancer. Cytogenet Genome Res 114, 279-83 (2006).
Moonen, P.M. et al. UroVysion compared with cytology and quantitative
cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 51,
1275-80; discussion 1280 (2007).
Bergman, J., Reznichek, R.C. & Rajfer, J. Surveillance of patients with bladder
carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int
101, 26-9 (2008).
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
Riesz, P. et al. Detection of bladder cancer from the urine using fluorescence in
situ hybridization technique. Pathol Oncol Res 13, 187-94 (2007).
Gudjonsson, S. et al. The value of the UroVysion assay for surveillance of nonmuscle-invasive bladder cancer. Eur Urol 54, 402-8 (2008).
Ferra, S. et al. Reflex UroVysion testing in suspicious urine cytology cases.
Cancer Cytopathol 117, 7-14 (2009).
Sullivan, P.S. et al. Comparison of ImmunoCyt, UroVysion, and urine cytology in
detection of recurrent urothelial carcinoma: a "split-sample" study. Cancer
Cytopathol 117, 167-173 (2009).
Mian, C. et al. ImmunoCyt: a new tool for detecting transitional cell cancer of the
urinary tract. J Urol 161, 1486-9 (1999).
Lodde, M. et al. Detection of upper urinary tract transitional cell carcinoma with
ImmunoCyt: a preliminary report. Urology 58, 362-6 (2001).
Vriesema, J.L. et al. Diagnostic efficacy of the ImmunoCyt test to detect
superficial bladder cancer recurrence. Urology 58, 367-71 (2001).
Olsson, H. & Zackrisson, B. ImmunoCyt a useful method in the follow-up
protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 35,
280-2 (2001).
Lodde, M. et al. Role of uCyt+ in the detection and surveillance of urothelial
carcinoma. Urology 61, 243-7 (2003).
Pfister, C. et al. ImmunoCyt test improves the diagnostic accuracy of urinary
cytology: Results of a French multicenter study. J Urol 169, 921-4 (2003).
Feil, G. et al. Accuracy of the ImmunoCyt assay in the diagnosis of transitional
cell carcinoma of the urinary bladder. Anticancer Res 23, 963-7 (2003).
Têtu, B., Tiguert, R., Harel, F. & Fradet, Y. ImmunoCyt/uCyt+ improves the
sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod
Pathol 18, 83-9 (2005).
Mian, C. et al. The value of the ImmunoCyt/uCyt+ test in the detection and
follow-up of carcinoma in situ of the urinary bladder. Anticancer Res 25, 3641-4
(2005).
Messing, E.M. et al. Performance of urine test in patients monitored for
recurrence of bladder cancer: a multicenter study in the United States. J Urol 174,
1238-41 (2005).
Mian, C. et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial
carcinoma: an update on 1991 analyses. Cancer 108, 60-5 (2006).
Lodde, M. et al. uCyt+ test: Alternative to cystoscopy for less-invasive follow-up
of patients with low risk of urothelial carcinoma. Urology 67, 950-4 (2006).
Soyuer, I., Sofikerim, M., Tokat, F., Soyuer, S. & Ozturk, F. Which urine marker
test provides more diagnostic value in conjunction with standard cytologyImmunoCyt/uCyt+ or Cytokeratin 20 expression. Diagn Pathol 4, 20 (2009).